FDA Rejections: We Read 200 CRLs So You Don’t Have To

The FDA's unprecedented release of 200 complete response letters (CRLs) for drugs that eventually gained approval offers critical insight into regulatory hurdles, highlighting common themes like manufacturing issues, quality control, and insufficient safety data. Specifically, Eli Lilly's Kisunla faced rejection over long-term safety data, Sarepta's Vyondys 53 due to questionable clinical benefit and serious safety concerns, and Gilead's Sunlenca over glass vial incompatibility. This 'radical transparency' provides investors with enhanced visibility into the FDA's stringent approval criteria and the specific challenges drug developers must overcome, underscoring the importance of robust clinical and manufacturing processes for market success.

Analysis

The FDA's unprecedented release of historical Complete Response Letters (CRLs) provides significant, granular insight into the regulatory risks faced by pharmaceutical companies, moving beyond boilerplate corporate press releases. The disclosed letters reveal that common reasons for initial rejection include manufacturing facility issues, quality control problems, and, most critically, safety concerns. The case studies exemplify the spectrum of these risks. Eli Lilly's (LLY) Alzheimer's drug, Kisunla, was initially rejected due to insufficient long-term safety data, with the FDA requiring 12-month data for at least 100 patients while Lilly had only provided it for 49. This highlights the high regulatory bar for chronic disease therapies. More severe issues were flagged for Sarepta's (SRPT) Vyondys 53, where the FDA's CRL questioned not only the drug's clinical benefit but also cited "potentially life-threatening" safety risks, including renal toxicity. This historical concern is particularly resonant given recent safety events with Sarepta's other gene therapies. In contrast, Gilead's (GILD) Sunlenca faced a delay due to a Chemistry, Manufacturing, and Controls (CMC) issue involving incompatible glass vials—a logistical problem rather than a fundamental flaw in the drug's safety or efficacy. This transparency allows investors to better differentiate between solvable operational hurdles and more profound biological or safety-related risks within a company's pipeline.

Key Decisions for Investors

• Investors should use these historical CRLs as a new due diligence tool to differentiate between the types of regulatory risk, assigning less weight to solvable manufacturing issues like Gilead's and more to fundamental safety or efficacy concerns like those raised for Sarepta.
• For Sarepta Therapeutics (SRPT), the 2019 CRL's mention of 'potentially life-threatening' toxicity establishes a concerning historical pattern given recent safety issues with its other therapies, warranting a higher risk premium on its pipeline.
• When assessing Eli Lilly (LLY) and others in the Alzheimer's space, pay close attention to the duration of patient safety monitoring in pivotal trials, as the Kisunla CRL demonstrates the FDA's stringent requirements can lead to significant delays.